<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274091</url>
  </required_header>
  <id_info>
    <org_study_id>28//2010</org_study_id>
    <nct_id>NCT01274091</nct_id>
  </id_info>
  <brief_title>Gene - Diet Interactions</brief_title>
  <acronym>Genediet</acronym>
  <official_title>Gene-diet Interactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marjukka Kolehmainen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interactions between genes and environment, i.e. our inherited responses to environmental&#xD;
      changes, may be crucial in the development of the common diseases. The investigators were the&#xD;
      first to identify PPARG gene as risk gene for type 2 diabetes. The role of the Pro12Ala&#xD;
      polymorphism in diabetes risk has also been verified in meta-analysis. However, this effect&#xD;
      on seems to depend on intervention and age. In this study the effects of diets high with&#xD;
      saturated fatty acids (SAFA) and polyunsaturated fatty acids (PUFA) are compared in subjects&#xD;
      carrying either Pro12Pro or Ala12Ala genotype of the PPARG gene.&#xD;
&#xD;
      Aim of the study:&#xD;
&#xD;
      To test if subjects with Pro12Pro and Ala12Ala genotypes respond differentially to a diet&#xD;
      supplemented with high saturated (SAFA) or polyunsaturated fat (PUFA).&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Specific: Subjects with the Ala12Ala genotype will be more sensitive to dietary&#xD;
           modification, and therefore respond more favorably to PUFA diet&#xD;
&#xD;
        2. More general: Dietary instructions individually tailored according to the genotype would&#xD;
           allow better treatment of obesity and diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity and type 2 diabetes are increasing in all western countries, including Finland.&#xD;
      Recent genome wide analyses have found &gt; 30 genes that contribute to either condition..&#xD;
      However, none of these genes explain &gt;5% of the disease risk and altogether they explain &lt;&#xD;
      10% of the total disease risk in cross-sectional studies. Therefore, diet and physical&#xD;
      activity are still the major determinants of the risk, as demonstrated by our earlier&#xD;
      intervention studies in order to find out the effect of different dietary modifications on&#xD;
      glucose and lipid metabolism. More importantly, interactions between genes and environment,&#xD;
      i.e. our inherited responses to environmental changes, may be crucial in the development of&#xD;
      the common diseases. Unfortunately, gene-environment interaction can only be effectively&#xD;
      investigated in intervention studies that are more expensive than cross-sectional population&#xD;
      screenings. This leads to a lower sample size and reduced power to detect effects of minor&#xD;
      alleles. Despite these limitations the investigators have been able to demonstrate&#xD;
      gene-intervention interactions for several genes, including PPARG, in the Finnish Diabetes&#xD;
      Prevention study. There is an urgent need for studies investigating effects of tailored diets&#xD;
      in individuals selected based on their genotype. This will be the next essential step leading&#xD;
      to improved dietary treatments guided by genetic information.&#xD;
&#xD;
      The investigators were the first to identify PPARG gene as risk gene for type 2 diabetes. The&#xD;
      role of the Pro12Ala polymorphism in diabetes risk has also been verified in meta-analysis.&#xD;
      However, this effect on seems to depend on intervention and age. Based on these findings the&#xD;
      investigators created in collaboration with Johan Auwerx an Pro12Ala animal model that&#xD;
      demonstrated a differential effect of dietary fat composition depending on the genotype.&#xD;
      However, an important conclusive proof that subjects selected based on their Pro12Ala&#xD;
      genotype would respond differently to specifically tailored diet modification is still&#xD;
      needed.&#xD;
&#xD;
      In this study the effects of diets high with saturated fatty acids (SAFA) and polyunsaturated&#xD;
      fatty acids (PUFA) are compared in subjects carrying either Pro12Pro or Ala12Ala genotype of&#xD;
      the PPARG gene. As a primary endpoint the investigators expect insulin sensitivity to alter&#xD;
      differently depending on the genotype. Additionally, a detailed characterization of energy,&#xD;
      glucose and lipid metabolism will be performed. Because PPARG gene plays a central role in&#xD;
      adipogenesis one of the aims of this study is to find new pathways, genes and gene clusters&#xD;
      that are regulated by PPARG in humans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 0</time_frame>
    <description>insulin sensitivity measured by oral glucose tolerance test at the beginning of the first, randomised diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 8</time_frame>
    <description>insulin sensitivty measured by oral glucose tolerance test after the first diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 10</time_frame>
    <description>Insulin sensitivity measured by oral glucose tolerance test in the beginning of the second, randomised diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>week 18</time_frame>
    <description>insulin sensitivity measured by oral glucose tolerance test after the second diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peripheral blood mononuclear cell gene expression</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral blood mononuclear cell gene expression</measure>
    <time_frame>week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>week 8</time_frame>
    <description>serum lipids, including serum lipidomics and fatty acid composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>week 18</time_frame>
    <description>serum lipids, including serum lipidomics and fatty acid composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>week 8</time_frame>
    <description>inflammation measured as serum cytokines and adipose tissue inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>week 18</time_frame>
    <description>inflammation measured as serum cytokines and adipose tissue inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy expenditure</measure>
    <time_frame>week 8</time_frame>
    <description>energy expenditure and the rates of substrate oxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy expenditure</measure>
    <time_frame>week 18</time_frame>
    <description>energy expenditure and the rates of substrate oxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue gene expression</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue gene expression</measure>
    <time_frame>week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>P/S-ratio 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:&#xD;
polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P/S-ration 0.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PUFA-diet</intervention_name>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.</description>
    <arm_group_label>P/S-ratio 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SAFA-diet</intervention_name>
    <description>Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.</description>
    <arm_group_label>P/S-ration 0.3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;20kg/m2 &lt;29kg/m2&#xD;
&#xD;
          -  Pro12Pro and Ala12Ala genotypes of PPARG Pro12Ala polymorphism&#xD;
&#xD;
          -  participation to METSIM-study (METabolic Syndrome in Men, currently &gt;10000 men&#xD;
             included from the population living in Kuopio, principal investigator Markku Laakso)&#xD;
&#xD;
          -  normoglycemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  type 2 diabetes&#xD;
&#xD;
          -  other chronic diseases&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jussi Pihlajam√§ki, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland, Kuopio University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula S Schwab, Clinical Lect, adjunct prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matti Uusitupa, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Eastern Finland</name>
      <address>
        <city>Kuopio</city>
        <zip>FIN-70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Eastern Finland</investigator_affiliation>
    <investigator_full_name>Marjukka Kolehmainen</investigator_full_name>
    <investigator_title>Senior scientist</investigator_title>
  </responsible_party>
  <keyword>Gene-diet interaction</keyword>
  <keyword>PPARgamma gene</keyword>
  <keyword>Pro12Ala</keyword>
  <keyword>Fatty acids</keyword>
  <keyword>Dietary modification</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

